Nurix Therapeutics Inc
$ 14.64
-4.19%
05 Jun - close price
- Market Cap 1,513,861,000 USD
- Current Price $ 14.64
- High / Low $ 15.57 / 14.24
- Stock P/E N/A
- Book Value 4.65
- EPS -3.17
- Next Earning Report 2026-07-08
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.32 %
- ROE -0.61 %
- 52 Week High 22.50
- 52 Week Low 8.20
About
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company is headquartered in San Francisco, California.
Analyst Target Price
$30.18
Quarterly Earnings
| Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 | Aug 2023 | May 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-08 | 2026-01-28 | 2025-10-09 | 2025-07-09 | 2025-04-08 | 2025-01-28 | 2024-10-11 | 2024-07-11 | 2024-04-10 | 2024-02-15 | 2023-10-12 | 2023-07-13 |
| Reported EPS | -0.79 | -0.82 | -1.03 | -0.52 | -0.67 | -0.75 | -0.67 | -0.71 | -0.76 | -0.77 | -0.68 | -0.45 |
| Estimated EPS | -0.8295 | -0.92 | -0.85 | -0.74 | -0.76 | -0.6689 | -0.68 | -0.63 | -0.8 | -0.5 | -0.74 | -0.57 |
| Surprise | 0.0395 | 0.1 | -0.18 | 0.22 | 0.09 | -0.0811 | 0.01 | -0.08 | 0.04 | -0.27 | 0.06 | 0.12 |
| Surprise Percentage | 4.7619% | 10.8696% | -21.1765% | 29.7297% | 11.8421% | -12.1244% | 1.4706% | -12.6984% | 5% | -54% | 8.1081% | 21.0526% |
Next Quarterly Earnings
| May 2026 | |
|---|---|
| Reported Date | 2026-07-08 |
| Fiscal Date Ending | 2026-05-31 |
| Estimated EPS | -0.73 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NRIX
2026-06-05 21:58:00
Nurix Therapeutics Inc. (NASDAQ: NRIX) shows weak near-term sentiment but potential long-term strength, according to Stock Traders Daily's AI analysis. The report identifies divergent sentiment across time horizons, suggesting choppy conditions, and provides specific entry, target, and stop-loss zones for position, momentum breakout, and risk hedging trading strategies.
2026-06-03 05:08:54
Christine Ring, Chief Legal Officer at Nurix Therapeutics (NASDAQ:NRIX), sold 8,148 shares of common stock for $135,252 on June 2, 2026, and also acquired 3,422 shares through exercising stock options for $6,364. These transactions were executed under a Rule 10b5-1 trading plan. The article also highlights recent positive analyst ratings and preclinical data presentations from Nurix Therapeutics.
2026-06-02 23:09:11
Nurix Therapeutics' Chief Legal Officer, Christine Ring, sold 8,148 shares of common stock at a weighted average price of $16.5995 per share under a pre-arranged Rule 10b5-1 trading plan. Concurrently, she exercised employee stock options for 3,422 shares at an exercise price of $1.86 per share. Following these transactions, Ring directly holds 13,579 shares of common stock and 5,221 employee stock options.
2026-06-02 23:09:11
Christine Ring, Chief Legal Officer at Nurix Therapeutics, sold 8,148 shares of common stock worth $135,252 at a weighted average price of $16.5995 per share. Concurrently, she acquired 3,422 shares by exercising employee stock options at $1.86 per share. These transactions were executed under a Rule 10b5-1 trading plan.
2026-06-02 20:09:11
Christine Ring, a Securities Compliance Counsel, has filed a Form 144 notice regarding the sale of Nurix Therapeutics (NRIX) common stock. The filing details multiple 10b5-1 sales executed in April and May 2026, including transactions of 3,368 shares for $57,118.25 and 5,394 shares for $90,406.68. It also lists the acquisition of shares through Restricted Stock Units, an Employee Stock Purchase Plan, and previously exercised options.
2026-05-18 21:39:26
BTIG has maintained its price target for Nurix Therapeutics at $30.00 per share. This indicates a continued positive outlook on the company's valuation from the investment firm.
